Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Amgen (AMGN) Share Price
News headlines about Amgen (NASDAQ:AMGN) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amgen earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 46.3984940093195 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- Zacks: Analysts Anticipate Amgen, Inc. (AMGN) to Announce $3.04 EPS (americanbankingnews.com)
- Amgen, Inc. (AMGN) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Top-notch Stocks to Watch: Juno Therapeutics, Inc. (JUNO), Amgen Inc. (AMGN) – Market Movers (financialqz.com)
- June 2019 Options Now Available For Amgen (AMGN) (nasdaq.com)
- See what the IHS Markit Score report has to say about Amgen Inc. (finance.yahoo.com)
Shares of Amgen (NASDAQ:AMGN) traded up $3.08 during trading hours on Friday, hitting $185.04. The stock had a trading volume of 3,082,770 shares, compared to its average volume of 2,710,000. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. Amgen has a twelve month low of $150.38 and a twelve month high of $191.10. The stock has a market capitalization of $134,320.00, a P/E ratio of 16.72, a P/E/G ratio of 2.70 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s revenue was down .7% on a year-over-year basis. During the same period in the prior year, the business earned $3.02 earnings per share. sell-side analysts forecast that Amgen will post 12.71 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be paid a $1.32 dividend. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a yield of 2.85%. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio is presently 41.55%.
Amgen declared that its board has approved a stock buyback plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.
A number of analysts have commented on AMGN shares. Cann reiterated a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Friday, October 6th. Bank of America boosted their target price on Amgen to $210.00 and gave the stock a “buy” rating in a research report on Thursday, October 5th. Mizuho reiterated a “buy” rating and set a $198.00 target price (up from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Jefferies Group reiterated a “buy” rating and set a $200.00 target price on shares of Amgen in a research report on Monday, September 25th. Finally, Oppenheimer reiterated a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $190.15.
In related news, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the transaction, the executive vice president now owns 56,106 shares of the company’s stock, valued at $9,921,223.98. The disclosure for this sale can be found here. Insiders sold 7,050 shares of company stock valued at $1,225,765 over the last quarter. Insiders own 0.19% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-amgen-amgn-share-price/1807292.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with Analyst Ratings Network's FREE daily email newsletter.